400-998-5282
专注多肽 服务科研

这是豆蔻酰化形式的自钙调蛋白肽 3 衍生抑制肽(AC3‑I),是钙调蛋白依赖性蛋白激酶 II(CaMKII)的高度特异性抑制剂,抗蛋白水解。AC3‑I 源自 CaMKII 底物自钙调蛋白肽 3,其第 9 位苏氨酸磷酸化位点被替换为丙氨酸。
编号:637302
CAS号:
单字母:Myristicacid-KKALHRQEAVDAL-OH
这是豆蔻酰化形式的自钙调蛋白肽 3 衍生抑制肽(AC3‑I),是钙调蛋白依赖性蛋白激酶 II(CaMKII)的高度特异性抑制剂,抗蛋白水解。AC3‑I 源自 CaMKII 底物自钙调蛋白肽 3,其第 9 位苏氨酸磷酸化位点被替换为丙氨酸。
This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.
烷基化肽-说明
专肽生物可提供多肽烷基化修饰,增加多肽一端的疏水性,例如常见的C18,C16,C14,C12,以及C6等,也可根据客户要求,接其他长度的烷基化链。
肉豆蔻酸修饰肽说明:
Myristyl group (Myristic acid), CH3(CH2)12–
肉豆蔻酸修饰肽的相关文献:
CPC Scientific serves as a supplier and partner to MYR Pharmaceuticals for developing bulevirtide (Hepcludex).
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
Buss, Colin G., and Sangeeta N. Bhatia. Proceedings of the National Academy of Sciences (2020).
European Commission (EC) Grants Conditional Marketing Authorization (CMA) for MYR Pharmaceuticals HEPCLUDEX®.
A comparison of modular PEG incorporation strategies for stabilization of peptide-siRNA nanocomplexes.
Lo, Justin H., et al. Bioconjugate Chemistry (2016).





